Article Text

Download PDFPDF

P062/119  Angiographic and clinical outcomes from 396 aneurysms treated with the pipeline flex embolization device with shield technology: subgroup analysis and FUP + preliminary experience with PED vantage
  1. Ivan Lylyk,
  2. Pedro Nicolas Lylyk,
  3. Nicolas Perez,
  4. Carlos Bleise,
  5. Javier Lundquist,
  6. Rodolfo Nella Castro,
  7. Esteban Scrivano,
  8. Pedro Lylyk
  1. ENERI-Clinica La Sagrada Familia, Buenos Aires, Argentina


Introduction PED-Shield was introduced to minimize thromboembolic complications. In this study, we investigated the safety and effectiveness of PED-Shield among all patients treated for intracranial aneurysms at our center.

Aim of Study Investigate the safety and effectiveness of PED-Shield among all patients treated for intracranial aneurysms at our center.

Methods This was a single-arm retrospective study of prospectively collected data of patients treated with PED-Shield at our high-volume center between January 2018–January 2021. The primary efficacy endpoint was complete occlusion as measured by a class 1 Raymond-Roy score at 1-year and 2-year follow-up. The primary safety endpoint was major morbidity and neurological mortality up to 1 year following intervention.

Results A total of 328 patients (mean age 56.1±14.7 years; 81.1% female), 80 of whom were previously included in PEDESTRIAN, with 396 aneurysms, were analyzed. A total of 378 devices were deployed, with 93.9% (372/396) of aneurysms requiring only one device. Follow-up angiography was available for 90.2% (296/328) of the procedures after a mean time of 14.0±8.2 months. Complete occlusion was demonstrated for 78.5% (132/168) of aneurysms at 12 months and 90.7% (98/108) at 24 months. The overall rates of major morbidity and neurological mortality after 2 years were 1.5% (5/328) and 0.6% (2/328), respectively.

Conclusion Our results demonstrate high rates of complete long-term occlusion among patients treated with PED-Shield. We also observed low rates of mortality and morbidity consistent with fewer thromboembolic complications with PED-Shield.

Disclosure of Interest Dr Pedro Lylyk is proctor and consultant for Medtronic.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.